You just read:

Jazz Pharmaceuticals to Present Phase 3 Data on JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy and with Obstructive Sleep Apnea, During 31st Annual SLEEP Meeting

News provided by

Jazz Pharmaceuticals plc

May 24, 2017, 16:05 ET